Generic Name and Formulations:
Cefprozil 250mg, 500mg; tabs.
Various generic manufacturers
Indications for Cefprozil:
Susceptible mild to moderate infections, including pharyngitis/tonsillitis, secondary bacterial infection of acute bronchitis, acute bacterial exacerbation of chronic bronchitis, acute sinusitis, skin and skin structure, otitis media.
≥13yrs: Pharyngitis/tonsillitis: 500mg every 24hrs. Acute sinusitis: 250mg (mild) or 500mg (moderate to severe) every 12hrs. Bronchitis: 500mg every 12hrs. Skin and skin structure: 250mg every 12hrs or 500mg every 12–24hrs. All: for 10 days. CrCl<30mL/min: 50% of standard dose.
Otitis media: <6 months: not recommended; 6 months to 12yrs: 15mg/kg every 12hrs. Acute sinusitis: <6 months: not recommended; 6months to 12yrs: 7.5mg/kg (mild) or 15mg/kg (moderate to severe) every 12hrs. Pharyngitis/tonsillitis: <2yrs: not recommended; 2–12yrs: 7.5mg/kg every 12hrs. Skin and skin structure: <2yrs: not recommended; 2–12yrs: 20mg/kg every 24hrs. All: for 10 days.
Penicillin or other allergy. Renal impairment, reduce dose. Monitor renal function. GI disease (esp. colitis). Labor & delivery. Pregnancy (Cat.B). Nursing mothers.
Avoid diuretics, other nephrotoxic drugs, including aminoglycosides. Potentiated by probenecid. May cause false (+) Clinitest.
GI upset, elevated liver enzymes, dizziness.
Formerly known under the brand name Cefzil.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Higher Doses of Image-Guided Neoadjuvant Radiation Therapy Found to Be Safe in Locally Advanced NSCLC: Study
- Supply Shortages of Bacillus Calmette-Guérin Found to Spur Drug Rationing in Non-Muscle-Invasive Bladder Cancer
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Epacadostat and Pembrolizumab Combo Active in Relapsed NSCLC
- PD-1 Inhibitor Cemiplimab Shows Antitumor Activity in Relapsed NSCLC